Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab: ongoing and future clinical development.

Antonio J Grillo-López1, Eric Hedrick, Michelle Rashford

  • 1Antonio J. Grillo-López, Consultant Clinical Research and Regulatory Strategy, Genentech, Inc, South San Francisco, CA 94080-4990, USA.

Seminars in Oncology
|February 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States.

EJHaem·2023
Same author

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.

Haematologica·2022
Same author

Flexible and Stretchable Bioelectronics.

Materials (Basel, Switzerland)·2022
Same author

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.

Breast cancer research and treatment·2021
Same author

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Blood·2018
Same author

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

The Lancet. Oncology·2018
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
Same journal

Stoma-free precision sphincter-preserving surgery with J-pouch for metastatic low rectal neuroendocrine tumor.

Seminars in oncology·2026
See all related articles

Rituximab, the first monoclonal antibody approved for cancer, has been used in over 125,000 patients. Ongoing research explores its use in combination therapies and for various malignant and non-neoplastic conditions.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibodies are established therapeutic agents.
  • Rituximab was the first monoclonal antibody approved by the US FDA for a cancer indication in 1997.
  • Rituximab is approved for CD20-positive B-cell non-Hodgkin's lymphoma in the US and Europe.

Purpose of the Study:

  • To review the clinical applications of rituximab.
  • To discuss ongoing and future clinical trials involving rituximab.
  • To highlight areas for further research and development of rituximab.

Main Methods:

  • Review of clinical research and trial data over 9 years.
  • Analysis of regulatory approvals and physician communications.
  • Synthesis of information on current and potential therapeutic uses.

Related Experiment Videos

Main Results:

  • Rituximab has been approved in 56 countries and used in over 125,000 patients in the US.
  • Significant clinical research has expanded the understanding of rituximab's applications.
  • The drug has spurred interest in other monoclonal antibody therapies.

Conclusions:

  • Rituximab has demonstrated significant therapeutic value in non-Hodgkin's lymphoma.
  • Further research is needed for combination therapies, multimodality regimens, and non-lymphoma applications.
  • The potential of monoclonal antibodies like rituximab in oncology and other fields is substantial.